About this item:

681 Views | 804 Downloads

Author Notes:

Email: john.mascarenhas@mssm.edu

Medical writing assistance was provided by Roland Tacke, PhD, CMPP, of Evidence Scientific Solutions, Philadelphia, PA, and funded by Incyte Corporation.

Subjects:

Research Funding:

Funding This study (NCT01633372) was sponsored by Incyte Corporation. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Keywords:

  • myelofibrosis
  • JAK1 inhibitor
  • INCB039110
  • bone marrow fibrosis

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.

Show all authors Show less authors

Tools:

Journal Title:

Haematologica

Volume:

Volume 102, Number 2

Publisher:

, Pages 327-335

Type of Work:

Article | Final Publisher PDF

Abstract:

Combined Janus kinase 1 (JAK1) and JAK2 inhibition therapy effectively reduces splenomegaly and symptom burden related to myelofibrosis but is associated with dose-dependent anemia and thrombocytopenia. In this open-label phase II study, we evaluated the efficacy and safety of three dose levels of INCB039110, a potent and selective oral JAK1 inhibitor, in patients with intermediate- or high-risk myelofibrosis and a platelet count ≥50×10(9)/L. Of 10, 45, and 32 patients enrolled in the 100 mg twice-daily, 200 mg twice-daily, and 600 mg once-daily cohorts, respectively, 50.0%, 64.4%, and 68.8% completed week 24. A ≥50% reduction in total symptom score was achieved by 35.7% and 28.6% of patients in the 200 mg twice-daily cohort and 32.3% and 35.5% in the 600 mg once-daily cohort at week 12 (primary end point) and 24, respectively. By contrast, two patients (20%) in the 100 mg twice-daily cohort had ≥50% total symptom score reduction at weeks 12 and 24. For the 200 mg twice-daily and 600 mg once-daily cohorts, the median spleen volume reductions at week 12 were 14.2% and 17.4%, respectively. Furthermore, 21/39 (53.8%) patients who required red blood cell transfusions during the 12 weeks preceding treatment initiation achieved a ≥50% reduction in the number of red blood cell units transfused during study weeks 1-24. Only one patient discontinued for grade 3 thrombocytopenia. Non-hematologic adverse events were largely grade 1 or 2; the most common was fatigue. Treatment with INCB039110 resulted in clinically meaningful symptom relief, modest spleen volume reduction, and limited myelosuppression.

Copyright information:

© Ferrata Storti Foundation

Export to EndNote